Thomas Stabb, a former executive at Triangle Pharmaceuticals, is the new chief financial officer at Inspire.
Stabb left Triangle after it was acquired recently by Gilead Sciences. He had been with Triangle for five years, serving most recently as acting CFO and vice president/treasure.
“We are very pleased that Tom has joined our management team,” said Christy Shaffer, chief executive officer of Inspire. “Tom’s broad experience will be of great value to Inspire as we continue to build the company and move toward commercializing our potential near-term products.”
Inspire recently raised $77 million as it prepares for possible FDA approval of an intranasal drug it has in Phase III clinical trials.
Stabb has participated in equity financing, mergers and acquisitions as well as taking drugs to market. He worked at PricewaterhouseCoopers before joining Triangle.
Inspire also announced the promotion of two other executives.
Dr. Benjamin Yerxa is senior vice president for discovery, being promoted from vice president. He has been with Inspire since 1995 after leaving Burroughs Wellcome.
Amy Schaberg is the new vice president of clinical research. She previously served as senior director of clinical research.
Inspire: www.inspirepharm.com
